Billionaire Cliff Asness’ Top 10 Healthcare Stock Picks
Cliff Asness is a billionaire investor and the co-founder and chief investment officer of AQR Capital Management, a quantitative hedge fund.
Neurocrine Biosciences Inc (NBIX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AQR Capital Management Cliff Asness | 4,938,967 | $650,659,396 | +51% | 0.3% |
| 2. | Two Sigma Advisors John Overdeck And David Siegel | 3,060,570 | $403,199,492 | +264% | 0.33% |
| 3. | Renaissance Technologies Jim Simons | 2,418,897 | $318,665,491 | +9% | 0.5% |
| 4. | Vestal Point Capital Ryan Wilder | 1,250,000 | $164,675,000 | 4.6% | |
| 5. | Millennium Management Israel Englander | 1,247,447 | $164,338,668 | +182% | 0.07% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.96 | 22,300 | $132,796.50 | 3,527,700 | 2011-10-12 | Filing | |
| $5.96 | 1,000 | $5,955.00 | 757,600 | 2011-10-12 | Filing | |
| $5.96 | 6,200 | $36,921.00 | 1,236,665 | 2011-10-12 | Filing | |
| $5.73 | 3,800 | $21,768.30 | 3,505,400 | 2011-10-11 | Filing | |
| $5.59 | 44,700 | $249,779.13 | 3,501,600 | 2011-10-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $181.02 | 4,367 | $790,514.34 | 16,225 | 2026-07-10 | Filing | |
| $179.60 | 10,000 | $1,796,014.00 | 54,729 | 2026-07-09 | Filing | |
| $178.72 | 8,433 | $1,507,134.80 | 16,225 | 2026-07-09 | Filing | |
| $178.54 | 2,737 | $488,672.19 | 16,225 | 2026-07-08 | Filing | |
| $178.57 | 3,401 | $607,305.01 | 16,225 | 2026-07-07 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 651,082 | $109,730,107 | 0.09% | |
| 2. | 222,606 | $37,516,902 | 0.05% | |
| 3. | 170,802 | $28,786,115 | 8.23% | |
| 4. | 82,486 | $13,901,778 | 0.09% | |
| 5. | 71,595 | $11,203,833 | 0.02% |
News See All
10 High Growth NASDAQ Stocks to Buy Now
On June 25, Ryan Detrick, Carson Group Chief Market Strategist, appeared on CNBC's 'Squawk Box' to discuss the latest market trends.
10 High Growth Stocks to Buy Right Now
On June 23, Chris Harvey of CIBC and Adam Parker of Trivariate joined CNBC's 'Closing Bell Overtime' to talk about the day's market action.
Is Neurocrine Biosciences, Inc. (NBIX) A Good Stock To Buy Now?
Is NBIX a good stock to buy? We came across a bullish thesis on Neurocrine Biosciences, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on NBIX.
15 Most Promising Stocks to Buy Right Now
Promising quality growth stocks are getting more attention as investors look for companies where growth expectations are still backed by earnings momentum, not just market excitement.
15 High Growth Stocks to Buy and Hold for the Next Decade
High-growth stocks are getting more attention as investors look beyond the first wave of AI winners and try to identify companies that can still compound earnings over a longer period.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2026 Earnings Call Transcript
Operator: Please standby, your meeting is about to begin. Hello and welcome everyone joining today's Neurocrine Biosciences, Inc. Q1 2026 Earnings Call.
Neurocrine Biosciences (NBIX) Announces First Presentation of New Two-Year Data From Phase 3 CAHtalyst® Adult Study
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best drug stocks to buy according to analysts. On April 22, Neurocrine Biosciences, Inc.
9 Best Drug Stocks to Buy According to Analysts
On April 27, Jurrien Timmer, director of global macro at Fidelity Investments, appeared on CNBC to talk about the market and oil prices, and how necessary it is for oil prices to retreat from their highs...
Truist Lowers Neurocrine Biosciences, Inc.'s (NBIX) PT Following 2026 Outlook Update
TheFly reported on February 17 that Truist reduced its price target on NBIX to $140 from $169 and maintained a Buy rating on the stock. The increase came after management's 2026 projection, and...
Hedge Fund Resource Center